drugset / Trial / NCT02168738

Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules

NCT02168738 ↗

Completed 4 enrolled Hospices Civils de Lyon
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules. The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.

Timeline

Start
2014-03
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AceDoPC Other / unclassified 50 mg Oral
Subject PC-DHA Other / unclassified 50 mg —
Subject TG-DHA Other / unclassified 50 mg Oral

Indications

No indication recorded.